Delegation of the German Eastern Business Association Visits Hemomont
27. March 2019.
Already on the first day of its stay in the Montenegrin capital, the Delegation of the German Eastern Business Association visited Hemomont within its several-day official visit to Montenegro and it also toured the SNUP production plant and talked to the company management.

The business delegation led by the Director of Association, Michael Harms, was made of the representatives of German companies and official institutions. A large group of businessmen from Germany is visiting Montenegro in the period from March 27 to 29 with the aim to discuss the economic situation and prospects of German-Montenegrin economic cooperation with Government officials and companies doing business there.

CEO of Hemofarm, Ronald Seeliger, had a dual role in this visit: as the President of the German-Serbian Chamber of Commerce, which has the competence over other neighbouring markets as well, he was the member of this delegation, while during the afternoon visit, he was a host, together with the management of Hemomont.

Snežana Perović, Tanja Vidić and Filip Trajković have presented, on behalf of Hemomont and together with the Chief Executive Officer of Hemofarm, the business operations and results of Hemomont, while a tour of the plant for production of sterile nasal sprays SNUP was especially pleasing. As the majority of members of this delegation has not have the chance so far to see the production of medicines and preparations live, especially not the sterile production, moments from preparing to enter the plant, being in a cold chamber, observing the process of sterilization, filling, all the way to packing of sprays, provoked great attention of guests.

Tour of the SNUP plant was completed with the visit of mobile rack warehouse with 2,600 pallet places, after which there was a one hour meeting of delegation members with hosts at which business results of the company, previous investments and plans for the forthcoming period were discussed as well as the standards that a pharmaceutical company should achieve in order to export products to the EU market.